Articles tagged "Malignancy"

2016 American Transplant Congress
Beyond the Bones – The Association Between Vitamin D, Graft Outcomes and Vascular Disease.
A. Cherukuri,¹ S. Balasubramanian,² R. Molyneux,² R. Baker.
¹UPMC, Pittsburgh; ²University of Leeds, Leeds, United Kingdom.
Background: Vitamin D deficiency in KTRs is an emerging theme. The purported associations between Vitamin D deficiency and various metabolic, cardiovascular and non-metabolic adverse events…
2016 American Transplant Congress
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.
R. Patel,¹ I. Feurer,¹ S. Karp,¹ L. Gillis,¹ H. Katzenstein,¹ H. Lovvorn III,¹ J. Pietsch,¹ D. Chung, G. Tiao,² D. Hanto.¹
¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Background: Hepatoblastoma (HB), hepatocellular carcinoma (HCC), along with hemangioendothelioma, hemangiosarcoma, and angiosarcoma (HHA) are rare tumors in children that are treated with orthotopic liver transplantation…
2016 American Transplant Congress
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.
D. Dahle,¹ T. Grotmol,² T. Leivestad,³ A. Hartmann,¹ G. Mjøen,¹ H. Pihlstrøm,¹ H. Næss,¹ H. Holdaas.¹
¹Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway; ²The Cancer Registry of Norway, Oslo, Norway; ³Norwegian Renal Registry, Oslo University Hospital, Oslo, Norway.
In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…
2016 American Transplant Congress
Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.
E. Maloney, E. Bongen, F. Vallania, N. Kotecha, P. Khatri, O. Martinez.
Stanford School of Medicine, Stanford, CA.
EBV is linked to a variety of lymphoid and epithelial malignancies. In transplant recipients EBV is associated with the development of B cell lymphomas in…
2016 American Transplant Congress
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.
S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; ³Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ⁴Renal Medicine, Monash Medical Centre, Melbourne, Australia; ⁵University of Queensland, Princess Alexandra Hospital, Queensland, Australia; ⁶Renal Medicine, Westmead Hospital, Sydney, Australia; ⁷WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; ⁸Novartis Pharmaceuticals, Sydney, Australia; ⁹Renal Medicine, Alfred Hospital, Melbourne, Australia.
A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
2016 American Transplant Congress
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.
S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
¹Institute of Health Policy, Management and Education, University of Toronto, Toronto, ON, Canada; ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada; ³Department of Surgery, St. Michael's Hospital, Toronto, ON, Canada; ⁴Department of Medicine, University Health Network, Toronto, ON, Canada.
Background: Pre-transplant malignancy (PTM) is considered a relative contraindication for transplantation due to the heightened risk of cancer recurrence associated with immunosuppression. However, little has…
2016 American Transplant Congress
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.
T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
¹Nephrology and Internal Intensive Care, Charite Campus Virchow Clinic, Berlin, Germany; ²Berlin-Brandenburg Center for Regenerative Therapies, Charite Campus Virchow Clinic, Berlin, Germany.
Alloreactive T-cells have been suggested to impact allograft outcome due to a higher incidence of acute rejection in the initial period after kidney transplantation. Knowledge…
2016 American Transplant Congress
Does Post-Transplant Adherence Come at a Cost?
K. Yadav, T. Nevins, D. Vock, W. Thomas, W. Robiner, A. Matas.
University of Minnesota, Minneapolis, MN.
Background: It is well documented that organ transplant (tx)recipients have an increased incidence of cancer including virus associated cancers like lymphoma. Our objective was to…
2016 American Transplant Congress
Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.
M. Grąt,¹ J. Stypułkowski,¹ W. Patkowski,¹ K. Wronka,¹ M. Wasilewicz,² K. Grąt,³ L. Masior,¹ M. Krasnodębski,¹ Z. Lewandowski,⁴ M. Krawczyk.¹
¹Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland; ²Department of General, Transplant and Liver Surgery, Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland; ³Second Department of Clinical Radiology, Medical University of Warsaw, Warsaw, Poland; ⁴Department of Epidemiology, Medical University of Warsaw, Warsaw, Poland.
Milan criteria are considered as benchmark for selection of patients with hepatocellular cancer (HCC) for liver transplantation. The aim of this study was to evaluate…
2016 American Transplant Congress
Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.
R. Anand, R. Hung, S. Frame, K. Bramham, M. Wain, A. Cronin.
Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
Organ transplant recipients are up to 200 times more likely to develop cutaneous squamous cell carcinoma (SCC) than age-matched general populations. Systemic retinoids, such as…